Korea Pharma's Pediatric ADHD Therapeutic Device Listed as Non-Reimbursable Item

The digital therapeutic device for Attention Deficit Hyperactivity Disorder (ADHD) in children, developed by Korea Pharma, has received an innovative medical technology prescription code from the Ministry of Health and Welfare.

On September 29, Korea Pharma announced that its ADHD digital therapeutic device, "Starrcus," has been included in the Ministry of Health and Welfare’s list of non-reimbursable innovative digital medical devices, and has been assigned the code "TX014."

The registered category is "Cognitive multitasking training for pediatric patients with Attention Deficit Hyperactivity Disorder using a digital therapeutic device." With clear prescription codes and fee standards now in place for the use of Starrcus in medical institutions, healthcare professionals are expected to have improved access to prescribe the device.

Starrcus is a game-based digital therapeutic device developed for the treatment of pediatric ADHD. Children diagnosed with ADHD can receive tailored cognitive training for four weeks through a mobile application, following a prescription from a healthcare professional. In November last year, Korea Pharma signed an exclusive domestic import and sales agreement for Starrcus with Emotive, a digital therapeutic device developer, further strengthening its portfolio in mental health treatments.

A representative from Korea Pharma stated, "A foundation has been established for utilizing Starrcus more systematically in clinical settings. Based on our established medical institution network in the central nervous system (CNS) field, we will continue to provide optimized integrated mental health solutions for pediatric patients and their guardians, expand the number of prescribing institutions, and further enhance patient accessibility."

This content was produced with the assistance of AI translation services.